Parent-reported social problems and clinician-evaluated adverse effects may be differentially affected by differing extended release methylphenidate formulations: a prospective, naturalistic study from Turkey

Basit Öğe Kaydı
dc.authorid0000-0002-3625-9888
dc.contributor.authorUytun, Merve Cikili.
dc.contributor.authorCetin, Fatih Hilmi.
dc.contributor.authorBabadagi, Zehra.
dc.date.accessioned2020-03-26T20:19:06Z
dc.date.available2020-03-26T20:19:06Z
dc.date.issued2019
dc.departmentSelçuk Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.description.abstractOBJECTIVE: Medikinet retard (R) is a nonosmotic, extended-release formulation of Methylphenidate (MPH) and has been used in Turkey for the last 4-5 years. The aim of our study is to compare the efficacy on functionality of Medikinet retard (R) and Concerta (R) and their adverse events. METHODS: Participants were referred to the Kayseri Training and Research Hospital and followed up there between August 2016 and June 2018. This study design is a 16-week prospective trial, each child received 16 weeks of OROS-MPH or MPH-ER. A total of 103 children were enrolled in the study, but only 70 children (n = 35 concerta, n = 35 medikinet retard) completed the study. Weiss Functional Impairment Rating Scale-Parent Report Form (WFIRS-P) and Barkley Side Effect Rating Scale (BSERS) were used for assessment. RESULTS: In both treatment groups, children improved significantly over time, both in intensity and in the number of problems. Regarding the social problems, Medikinet retard (R) was superior to the Concerta in terms of effects. The side effects of insomnia and euphoria were seen more common in the Concerta (R) group than the Medikinet retard (R). Additionally, the mean severity scores of euphoria were shown higher in the Concerta (R) group than the Medikinet retard. CONCLUSION: From this study, we concluded that Medikinet retard (R) is also an effective and safety MPH formulation.en_US
dc.identifier.citationCikili Uytun, M., Çetin, F. H., Babadağı, Z. (2019). Parent-Reported Social Problems and Clinician-Evaluated Adverse Effects may be Differentially Affected by Differing Extended Release Methylphenidate Formulations: A Prospective, Naturalistic Study from Turkey. Psychiatry and Clinical Psychopharmacology, 29(4), 722-729.
dc.identifier.doi10.1080/24750573.2019.1609153en_US
dc.identifier.endpage729en_US
dc.identifier.issn2475-0573en_US
dc.identifier.issn2475-0581en_US
dc.identifier.issue4en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage722en_US
dc.identifier.urihttps://dx.doi.org/10.1080/24750573.2019.1609153
dc.identifier.urihttps://hdl.handle.net/20.500.12395/38069
dc.identifier.volume29en_US
dc.identifier.wosWOS:000470379400001en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.institutionauthorCetin, Fatih Hilmi.
dc.language.isoenen_US
dc.publisherTAYLOR & FRANCIS LTDen_US
dc.relation.ispartofPSYCHIATRY AND CLINICAL PSYCHOPHARMACOLOGYen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectMethylphenidateen_US
dc.subjectConcertaen_US
dc.subjectMedikinet retarden_US
dc.subjectADHDen_US
dc.subjectsocialen_US
dc.subjectfunctionalityen_US
dc.titleParent-reported social problems and clinician-evaluated adverse effects may be differentially affected by differing extended release methylphenidate formulations: a prospective, naturalistic study from Turkeyen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Merve Cikili UYTUN.pdf
Boyut:
1.12 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Full Text Access
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
Çocuk ve Ergen Ruh Sağlığı ve Hastalıkları/Makale Koleksiyonu